Study to Assess GTAEXS617 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2028-05-01
Target enrollment:
Participant gender:
Summary
A phase 1/2 study to assess the safety, tolerability, pharmacokinetics and anti-tumor
activity of GTAEXS617-001 in patients with advanced solid tumors.